Sustained clinical response in a patient with metastatic breast cancer treated with MP0274
Today we celebrate the success of our colleague, and Scientific Advisory Board member, Dr Samson Fung. Dr Fung was recently co-authored in a publication by JCO Precision Oncology released on 4th November, 2022, for his work as a study director in a Ph I FIH clinical study in patients with metastatic breast cancer.
Believed to be the first report of sustained clinical response in a patient with metastatic breast cancer treated with MP0274, you can learn more about this work here:
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab